Trinity Biotech plc announced a 1-for-30 reverse ADS split, changing the ratio from 1 ADS for 20 Class A shares to 1 ADS for 600 Class A shares, effective at the market open on July 24, 2026, to regain Nasdaq’s $1.00 minimum bid price requirement. The move requires holders to exchange every thirty old ADSs for one new ADS, with fractional entitlements being sold for cash and distributed to shareholders. Management expects the adjusted ADS price to rise proportionally, aiming to broaden investor access and improve trading dynamics, though no guarantee is given on reaching a price above prior levels. The company has faced ongoing financial challenges, including weak profitability and cash burn, which have contributed to a historically low share price and questions about overall valuation. These reports consistently note Trinity Biotech operates in the medical diagnostics space and has a relatively small market capitalization, underscoring the higher risk associated with the reverse split strategy. Market coverage from multiple outlets highlights the anticipated administrative steps, potential market perception shifts, and investor considerations surrounding the NASDAQ compliance move.